Advertisement

Indian Journal of Clinical Biochemistry

, Volume 33, Issue 4, pp 382–386 | Cite as

Serum Biomarker Based Algorithms in Diagnosis of Ovarian Cancer: A Review

  • Suchitra Kumari
Review Article

Abstract

Epithelial ovarian cancer accounts for more than 90% of ovarian tumours and continues as a leading cause of death from gynaecological malignancies. It is often difficult to differentiate a benign ovarian mass from malignant ones. Invasive histopathological biopsy is used as the gold standard diagnostic tool to diagnose cancer in patients with ovarian mass. A wide spectrum of Biomarkers were tried in various studies to develop a non invasive diagnostic tool, out of which HE4 and CA 125 remain the only clinically useful biomarker. Consequently various Biomarker based algorithms i.e. Risk of Malignancy Index, risk of ovarian cancer algorithm, OVA1, risk of malignancy algorithm were generated that have been developed to assess the risk of a mass being malignant. These algorithms help in timely triage of patients. Recently in 2016 FDA cleared Ova1 test (OVERA) with CA 125-II, HE4, apolipoprotein A-1, FSH, and transferring (Sensitivity 91% and Specificity 69%) as a referral or Triage test in patients presenting with ovarian mass. Combination of protein and circulating Micro RNA analysis in blood, could provide a comprehensive screening and diagnostic panel, in management of patients presenting with ovarian mass in one clinical setting.

Keywords

Epithelial ovarian cancer Biomarkers Biomarker based algorithms Circulating Micro RNA 

Notes

Compliance with Ethical Standards

Conflict of interest

Author declares that they have no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by the authors.

Human and Animal Right Statement

For this type of study formal consent is not required. This article does not contain any studies with human participants or animals performed by the authors.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.  https://doi.org/10.3322/caac.21442 Epub 2018 Jan 4.CrossRefPubMedGoogle Scholar
  2. 2.
    Martina M, Elisa D, Orazio R, Valentina B, Teresita N, Matte G, et al. The ROMA (Risk of ovarian Malignancy algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011;49(3):521–5.Google Scholar
  3. 3.
    Perez LFR, Chedraui P, Troyano LJM. Peri and post- menopausal incidental adnexal masses and the risk of sporadic ovarian malignancy, new insight and clinical management. Gynecol Endocrinol. 2010;26:631–43.CrossRefGoogle Scholar
  4. 4.
    Robert CBJ, Steven S, Anna L, Richard GM. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer. 2012;22(1):S5–8.Google Scholar
  5. 5.
    Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, et al. Serum biomarker panel for the determination of Benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010;117(3):440–5.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Van GT, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA 125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of ovarian Malignancy algorithm. Br J Cancer. 2011;104(5):863–70.CrossRefGoogle Scholar
  7. 7.
    Kim YM, Whang DH, Park J, Kim SH, Lee SW, Park HA, et al. Evaluation of the accuracy of human epididymis protein 4(HE4) in combination with CA 125 for detecting ovarian cancer-a prospective case control study in a Korean population. Clin Chem Med. 2011;49(3):527–34.Google Scholar
  8. 8.
    Bandiera E, Romani C, Specchia C, Zanoti L, Galli C, Ruggeri G, et al. Serum human epididymis protein 4(HE4) and risk of ovarian malignancy algorithm (ROMA) as new diagnostic and prognostic tool for epithelial ovarian cancer management. Cancer Epidemiol Biomark Prev. 2011;20(12):2496–506.CrossRefGoogle Scholar
  9. 9.
    Su F, Kozak KR, Imaizumi S, Satoshi I, Gaoa F, Malaika WA, et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Nat Acad Sci USA. 2010;107(46):19997–20002.  https://doi.org/10.1073/pnas.1009010107.CrossRefPubMedGoogle Scholar
  10. 10.
    Takaishi S, Wang TC. Gene expression profiling in a mouse model of helicobacter-induced gastric cancer. Cancer Sci. 2007;98:284–93.CrossRefPubMedGoogle Scholar
  11. 11.
    Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J, et al. Validation of serum biomarkers for detection of early stage ovarian cancer. Am J Obstet Gynecol. 2009;200(6):639.e1–5.  https://doi.org/10.1016/j.ajog.2008.12.042 Epub 2009 Mar 14.CrossRefGoogle Scholar
  12. 12.
    Tuft SH, Nymoen DA, TE Hetland F, Kaern J, Trope CG, Davidson B. APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival. Am J Clin Pathol. 2014;142(1):51–7.CrossRefGoogle Scholar
  13. 13.
    Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumour biomarkers for the detection of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang B, Barekati Z, Kohler C. Proteomics and biomarkers for ovarian cancer diagnosis. Ann Clin Lab Sci. 2010;40:218–25.PubMedGoogle Scholar
  15. 15.
    Frederick RU. A perspective on ovarian cancer biomarkers: past, present and yet-to-come. Diagnostics (Basel). 2017;7(1):14.  https://doi.org/10.3390/diagnostics7010014.CrossRefGoogle Scholar
  16. 16.
    Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011;118(2 Pt 1):280–8.  https://doi.org/10.1097/AOG.0b013e318224fce2.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Macuks R, Baidekalna I, Gritcina J, Avdejeva A, Donina S. Apolipoprotein A1 and transferrin as biomarker in ovarian cancer diagnostics. Acta Chirurgica Latviensis. 2010;10(2):16–20.  https://doi.org/10.2478/v10163-011-0003-3.CrossRefGoogle Scholar
  18. 18.
    Brian MN, Anna EL. Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Mol Diagn Ther. 2013;17(3):139–46.  https://doi.org/10.1007/s40291-013-0027-6.CrossRefGoogle Scholar
  19. 19.
    Yang WL, Zhen L, Robert CB. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn. 2017;17(6):577–91.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Meredith CH, Michael S, Sherri B, Quynh T, Elias L, Malpuri R, et al. A combinatorial proteomic biomarker assay to detect ovarian cancer in women. Biomark Cancer. 2018;10:1–16.  https://doi.org/10.1177/1179299X18756646.CrossRefGoogle Scholar
  21. 21.
    Meenal R, Sameer G, Manisha S. Biomarkers towards ovarian cancer diagnostics: present and future prospects. Braz Arch Biol Technol. 2016;59:1–15.  https://doi.org/10.1590/1678-4324-2016160070.CrossRefGoogle Scholar
  22. 22.
    Ann RH, Gunnar K, Andy E, Cybil A, Maria PBG, Philip B, et al. Evaluation of prognostic and predictive significance of circulating micrornas in ovarian cancer patients. Dis Mark. 2017;3:1–9.  https://doi.org/10.1155/2017/3098542.CrossRefGoogle Scholar
  23. 23.
    Hentze JL, Hogdall C, Kjaer SK, Blaakaer J, Hogdall E. Searching for new biomarkers in ovarian cancer patients: rationale and design of a retrospective study under the Mermaid III project. Contemp Clin Trials Commun. 2017;13(8):167–74.  https://doi.org/10.1016/j.conctc.2017.10.003 Ecollection 2017 Dec.CrossRefGoogle Scholar
  24. 24.
    Marta L, Rui P, Susanne B, Ulla E, Sonja G, Christina B. Platelet protein biomarker panel for ovarian cancer diagnosis. Biomark Res. 2018;6:2.  https://doi.org/10.1186/s40364-018-0118-y.CrossRefGoogle Scholar
  25. 25.
    Karen HL. Screening for ovarian cancer in asymptomatic women. JAMA. 2018;319(6):557–8.  https://doi.org/10.1001/jama.2017.21894.CrossRefGoogle Scholar
  26. 26.
    Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926–30.  https://doi.org/10.1126/science.aar3247 Epub 2018 Jan 18.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: updated evidence report and systematic review for the us preventive services task force. JAMA. 2018;319(6):595–606.  https://doi.org/10.1001/jama.2017.21421.CrossRefPubMedGoogle Scholar
  28. 28.
    Montagnana M, Benati M, Danese E. Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective. Ann Transl Med. 2017;5(13):276.  https://doi.org/10.21037/atm.2017.05.13.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Pendlebury A, Hannan NJ, Binder N, Beard S, Mcgauran M, Grant P, et al. The circulating microRNA-200 family in whole blood are potential biomarkers for high-grade serous epithelial ovarian cancer. Biomed Rep. 2017;6(3):319–22.  https://doi.org/10.3892/br.2017.847 Epub 2017 Jan 25.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kafshdooz L, Pourfathi H, Akbarzadeh A, Kafshdooz T, Razban Z, Sheervalilou R, et al. The role of microRNAs and nanoparticles in ovarian cancer: a review. Artif Cells Nanomed Biotechnol. 2018;23:1–7.  https://doi.org/10.1080/21691401.2018.1454931 [Epub ahead of print] PMID: 29569937.CrossRefGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2018

Authors and Affiliations

  1. 1.Department of BiochemistryAll India Institute of Medical Sciences (AIIMS)Sijua, BhubaneswarIndia

Personalised recommendations